The vaccination resulted in a production of neutralizing antibodies against JCV, which correlated with resolution of PML progression in brain MRI, induction of robust JCV VP-1 specific CD4 T cell proliferation, substantial reductions in JCV DNA viral load in CSF, and showed an overall improvement of clinical symptoms (47). This evidence concerns the gene CD4 and progressive multifocal leukoencephalopathy.